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McCaffrey, Dindyal Mandal, and Keykavous Parang*
Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of
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Abstract
Gold nanoparticles (AuNPs) were synthesized in situ in a green and rapid method from the
reaction of reducing linear and cyclic peptides containing tryptophan and lysine residues, (KW)5
and cyclic [KW]5, with an aqueous solution of HAuCl4 and were evaluated as cellular nanodrug
delivery systems. The cyclic or linear nature of the peptide was found to determine the
morphology and size of the formed peptide-AuNPs and their in vitro molecular transporting
efficiency. While cyclic [KW]5-AuNPs formed sponge-like agglomerates, linear (KW)5-AuNPs
demonstrated ball-shaped structures. A comparative flow cytometry study showed that the cellular
uptake of fluorescence-labeled anti-HIV drugs (emtricitabine (FTC) and lamivudine (3TC)) in
human Leukemia (CCRF-CEM) cells, and a negatively charged cell-impermeable phosphopeptide
(GpYEEI) in human ovarian adecarcinoma (SK-OV-3) cells was significantly higher in the
presence of cyclic [KW]5-AuNPs than that of linear (KW)5-AuNPs, parent cyclic [KW]5, and
linear (KW)5 peptides. For example, the cellular uptake of F′-GpYEEI was enhanced 12.8-fold by
c[KW]5-AuNPs. Confocal microscopy revealed the localization of fluorescence-labeled-3TC in
the presence of c[KW]5-AuNPs mostly in nucleus in SK-OV-3 cells after 1 h. On the other hand,
l(KW)5-AuNPs delivered fluorescence-labeled-3TC in cytoplasm. These data suggest that non-cell
penetrating peptides can be converted to efficient molecular transporters through peptide-capped
AuNPs formation.
Keywords
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Introduction
The cellular delivery of hydrophobic and poorly water-soluble compounds to enhance the
efficacy using Drug delivery systems (DDS) is a subject of major interest.1 Among all
delivery systems, nuclear targeting nanodrug delivery systems (nano-DDS) have attracted
significant attention. Common approaches in gene therapy involve using DNA as a
pharmaceutical agent to replace or correct a mutated gene.2 Moreover, the nucleus is a target
for a diverse number of anticancer and antiviral drugs,3 due to the presence of the genetic
information and transcription systems.
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The nuclear membrane (envelope) is composed of a double lipid bilayer that works as a
physical barrier between cell nucleus content and the cytoplasm. The nuclear membrane
contains many nuclear pore complexes (NPCs) that facilitate and regulate the exchange of
proteins and RNA between the cell nucleus and the cytoplasm. Depending on the cell line,
NPCs have different sizes from 20 to 60 nm.4 Although NPCs operate as available passages
for all exchange between the nucleoplasm and cytoplasm, they can be exploited as pathways
for nanoparticle delivery.5,6 Therefore, the delivery of the therapeutic agents to the nucleus
by using nano-DDS offers several advantages compared to other systems.
The application of prodrug strategy among researchers is now well established. Prodrugs are
chemically modified analogous of the active metabolite that can improve pharmacokinetics
and pharmacodynamic (PK/PD) properties of the active drug. However, intracellular
chemical transformation needs to be occurred in the presence of different enzymes to
convert prodrugs to their corresponding pharmacologically potent compounds in in vivo
systems. Prodrug approach offers several advantageous, such as enhancing water solubility,
improved chemical stability, decreased toxicity, and insufficient brain penetration.7
Gold nanoparticles (AuNPs) have received an increased attention due to their unique
potential use as nano-DDS.8 Most of the known AuNPs as nano-DDS lead to the
intracellular localization of nanoparticles mainly in the cytoplasm.9 However, appropriate
functionalization of AuNPs with other compounds can be used for their optimization as
nano-DDS for a specific application.
Peptide-mediated drug delivery has been widely used for a broad range of cargo molecules
including drugs, siRNA, and genes due to their versatility and the presence of a wide range
of amino acids.10 Thus, the peptides have the potential to be used for decoration of the
surface of metal nanoparticles. Recently, AuNPs functionalized by peptides have been used
as biocompatible systems in drug delivery.11 For example, AuNPs capped by linear Tat was
reported to be able to get internalized into the cytoplasm of 3T3 and HepG2 cells.11c
After the localization of DDS in the destination, it should release the cargo. Thus, drug
loading and release issues are critical for optimized DDS function. Two major strategies for
drug loading include covalent and non-covalent binding between AuNPs and drugs.12 Non-
covalent loading offers two main advantages, including ease of the drug loading and
facilitating drug release in intact form over covalent loading.13 Thus, the entrapment of
unmodified drugs into functionalized AuNPs through non-covalent interaction is introduced
as one of the prodrug strategies for the delivery of a broad range of drugs. Employing
appropriate surface functionalization provides a hydrophobic pocket for the loading of
drugs.
We have previously reported cyclic peptides containing alternative arginine (R) and
tryptophan (W) as efficient molecular transporters that showed improving the cellular uptake
of different cargos.14 Subsequently, it was found that a physical mixture of the cell-
penetrating cyclic peptide [WR]4 and HAuCl4 led to the formation of peptide-capped gold
nanoparticles (P-AuNPs) and enhanced the cellular uptake of drugs significantly.15 It
remains to be determined whether non-cell penetrating peptides can be converted to a
nuclear targeting DDS through generation of peptide-AuNPs.
Herein, we report the generation of a novel nuclear-targeting nano-DDS containing AuNPs
and a non-cell penetrating peptide containing alternative lysine and tryptophan residues. The
presence of these amino acids was found to be appropriate to generate in situ biocompatible
AuNPs. To the best of our knowledge, this is the first report of converting a non-cell
penetrating peptide to an efficient nuclear targeting nano-DDS through cyclic peptide-
capped AuNPs formation.
Shirazi et al. Page 2
Mol Pharm. Author manuscript; available in PMC 2014 August 05.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Experimental Section
General
All reactions were carried out in Bio-Rad polypropylene columns by shaking and mixing
using either a Glass-Col small tube rotator or PS3 automated peptide synthesizer in dry
conditions at room temperature unless otherwise stated. In general, all cyclic and linear
peptides were synthesized by the solid-phase synthesis strategy employing N-(9-
fluorenyl)methoxycarbonyl (Fmoc)-based chemistry and Fmoc-L-amino acid building
blocks. 2-(1H–Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
(HBTU) and N,N-diisopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF) were
used as coupling and activating reagents, respectively. 2-Chlorotrityl chloride resin, Fmoc-
amino acid trityl chloride resins, coupling reagents, and Fmoc-amino acid building blocks
were purchased from Chempep (Miami, FL). Other chemicals and reagents were purchased
from Sigma-Aldrich Chemical Co. (Milwaukee, WI). Fmoc deprotection at each step was
carried out using piperidine in DMF (20%). Side chain protected peptides were cleaved from
the resins by shaking the resins with a mixture of trifluoroethanol (TFE)/acetic acid/
dichloromethane (DCM) (1:2:7 v/v/v, 15 ml) for 2 h. The resins were filtered off, and the
liquid was evaporated to dryness to get side-chain protected linear peptide. Generally, the
cyclization of the peptides was carried out in the presence of a mixture of 1-hydroxy-7-
azabenzotriazole (HOAt) and N,N′-diisopropylcarbodiimide (DIC) in dry DMF and dry
dichloromethane (DCM) for 24 h. DMF and DCM were evaporated. The side chain
deprotection was carried with TFA/thioanisole/anisole/1,2-ethanedithiol (EDT) (90:5:2:3 v/
v/v/v) for 2 h. The crude peptides were precipitated by the addition of cold diethyl ether
(Et2O) and were purified by using a reversed-phase Hitachi HPLC (L-2455) on a
Phenomenex Prodigy 10 μm ODS reversed-phase column (2.1 cm × 25 cm) and a gradient
system. The peptides were separated by eluting the crude peptides at 10.0 mL/min using a
gradient of 0-100% acetonitrile (0.1% TFA) and water (0.1% TFA) over 60 min, and then
were lyophilized to yield cyclic peptides (Figure 1). The purity of final products (≥95%) was
confirmed by analytical HPLC. The analytical HPLC was performed on a Hitachi analytical
HPLC system using a C18 Shimadzu Premier 3 μm column (150 cm × 4.6 mm) and a
gradient system (water/CH3CN), and a flow rate of 1 mL/min with detection at 220 nm. The
chemical structures of final products were confirmed by high-resolution MALDI AXIMA
performance TOF/TOF mass spectrometer (Shimadzu Biotech) or a high-resolution
Biosystems QStar Elite time-of-flight electrospray mass spectrometer. As a representative
example, the synthesis of linear (KW)4 is outlined here.
Synthesis of Linear (KW)4 and Linear (KW)5—Fmoc-Trp(Boc)-Wang resin (555 mg,
0.54 mmol/g, 0.3 mmol) was swelled in anhydrous DMF for about 15 min under dry
nitrogen. The excess of the solvent was filtered off. The swelling and filtration steps were
repeated for 2 more times before the coupling reactions. Fmoc-Lys(Boc)-OH (325 mg, 0.75
mmol) was coupled to the N-terminal of tryptophan Wang resin in the presence of HBTU
(285 mg, 0.75 mmol) and DIPEA (262 μL, 1.50 mmol) in DMF (7 mL) by mixing for 1.5 h.
After the coupling was completed, the reaction solution was filtered off, and the resin was
collected by filtration and washed with DMF (7 × 15 mL), followed by N-terminal Fmoc
deprotection using piperidine in DMF (20% v/v, 10 mL, 2 times, 5 and 10 min). The resin
was washed with DMF (7 × 15 mL). The subsequent amino acids, Fmoc-Trp(Boc)-OH (395
mg, 0.75 mmol) and Fmoc-Lys(Boc)-OH (325 mg, 0.75 mmol), were coupled alternatively
three times, respectively, in a similar manner (Scheme S1). Fmoc-deprotection at the N-
terminal was carried out in the presence of piperidine in DMF (20% v/v, 10 mL, 2 × 10 min)
to afford the linear peptide on solid phase. The resin was washed with DMF and DCM
respectively (each 2 × 25 mL). The resins were dried under vacuum for 24 h. Fresh cleavage
cocktail, reagent R, TFA/thioanisole/EDT/anisole (90:5:3:2 v/v/v/v, 10 mL), was added to
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the resins. The mixture was shaken at room temperature for 2 h. The resin was collected by
filtration and washed with another 2 mL of cleavage cocktail. Combined filtrates were
evaporated to a minimum volume under dry nitrogen. The crude peptide was precipitated by
the addition of cold diethyl ether (75 mL, Et2O), lyophilized, and purified by reversed-phase
Hitachi HPLC (L-2455) on a Phenomenex Prodigy 10 μm ODS reversed-phase column (2.1
cm × 25 cm) using a gradient system as described above to yield linear (KW)4. MALDI-
TOF (m/z) [C68H90N16O9]: calcd, 1274.7077; found, 1275.1780 [M + H]+, 1297.1747 [M +
Na]+. A simliar procedure was performed for the synthesis of the linear (KW)5. l(KW)5:
MALDI-TOF (m/z) [C85H112N20O11]: calcd, 1588.8819; found, 1589.7442 [M + H]+,
1611.7890 [M + Na]+, 1627.7601 [M + K]+.
Synthesis of Cyclic Peptides—The synthesis of cyclic peptides was carried out
according to the previously reported procedure.14,16 As a representative example, the
synthesis of cyclic [KW]4 is described here.
Cyclic [KW]4—The linear protected peptide (KWKWKWKW) was assembled on the H-
Trp(Boc)-2-chlorotrityl chloride resin (975 mg, 0.41 mmol/g) in 0.40 mmol scale as
described above. After the final deprotection of the N-terminal Fmoc group by piperidine in
DMF (20% v/v, 15 mL, 2 times, 5 and 10 min), the side chain protected peptide was cleaved
from assembled trityl resin in the presence of the cleavage cocktail TFE/acetic acid/DCM
(1:2:7 v/v/v, 50 mL) by shaking for 1 h at room temperature to yield the side chain protected
linear peptide. The filtrates were evaporated to dryness under reduced pressure. To the
residue was added hexane (2 × 25 mL) and DCM (1 × 25 mL) to remove the acetic acid
from the mixture and to solidify the crude material as white solid. The crude protected
peptide was dried under vacuum overnight. Examining a small portion of the crude by
MALDI analysis confirmed the formation of the linear protected peptide. Thus, the crude
was used directly for the cyclization reaction. The dried crude linear protected peptide was
dissolved in DMF/DCM (2:1 v/v, 150 mL). HOAt (135 mg, 1 mmol) and DIC (137 μL, 0.88
mmol) were added to the mixture, and the solution was stirred for 12 h under the nitrogen
atmosphere. After completion of the cyclization as confirmed by the MALDI-TOF, the
solvents were removed under reduced pressure on a rotary evaporator. The crude product
was dried overnight in vacuum before the final cleavage. Freshly prepared cleavage cocktail,
reagent R, TFA/thioanisole/EDT/anisole (90:5:3:2 v/v/v/v, 15 mL) was added to the crude
product. The mixture was stirred at room temperature for 2 h. The cleavage cocktail was
concentrated to a minimum volume under reduced pressure by a rotary evaporator. After
precipitation of crude peptide in cold diethyl ether (75 mL, Et2O) and centrifugation, the
crude peptide was lyophilized and purified by reversed-phase Hitachi HPLC (L-2455) on a
Phenomenex Prodigy 10 μm ODS reversed-phase column (2.1 cm × 25 cm) using a gradient
system to yield cyclic [KW]4. A similar procedure was employed for the synthesis of other
cyclic peptides by using appropriate resins and protected amino acids. The mass spectra data
for c[KW]5, c[KF]4, c[KA]4, c[RFEF]2, and c[KE]4 have been previously reported by us.16
c[KW]4—MALDI-TOF (m/z) [C68H88N16O8]: calcd, 1256.6971; found, 1257.2083 [M +
H]+, 1281.2555 [M + H + Na]+, 1295.2420 [M + K]+; C[EL]4: HR-MS (ESI-TOF) (m/z):
C44H72N8O16 calcd, 968.5066 ; found, 969.4220 [M + H]+, 485.2551 [M + 2H]2+; C[RF]4:
HR-MS (ESI-TOF) (m/z): C60H84N20O8: calcd, 1212.6781; found, 1212.6052 [M + H]+,
607.3026 [M + 2H]2+, 405.5428 [M+ 3H]3+, 304.1588 [M + 4H]4+; C[RC]4: HR-MS (ESI-
TOF) (m/z): C36H68N20O8S4 calcd, 1036.4412; found, 1037.4096 [M + H]+, 345.1323 [M +
3H]3+, 259.1024 [M + 4H]4+.
Synthesis of Fluorescence Labeled-βA-Cyclic[KWKWKWKWKW] (F′- [KW]5)—
The linear peptide (Dde-K(Fmoc)-WKWKWKWKW) was assembled on solid phase using
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Fmoc/tBu solid phase methodology. Appropriately protected amino acids were assembled
on H-Trp(Boc)2 chlorotrityl resin (513 mg, 0.40 mmol, 0.78 mmol/g) according to the solid-
phase synthesis strategy described above. Dde-Lys(Fmoc)-OH was used at the N-terminal of
the peptide. The Fmoc protecting group was removed from the side chain of lysine using
piperidine in DMF (20%, 10 mL, 2 times, 5 and 10 min) and a short linker Fmoc-β-alanine
(312 mg, 1 mmol) was coupled with the unprotected side chain amine group of lysine using
HBTU/DIPEA (380 mg, 1 mmol/349 uL, 2 mmol) in DMF (8 mL). Fmoc of β-alanine was
removed in the presence of piperidine in DMF (20%, 10 mL, 2 times, 5 and 10 min) to
attach carboxyfluorescein. 5(6)-Carboxyfluorescein diisobutyrate (CFDI, US Biological)
(516 mg, 1 mmol) was used for labeling the peptide. This was achieved by adding resin-
bound linear peptide (0.4 mmol) into a solution of CFDI (516 mg, 1 mmol),
azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP, 520 mg,
1 mmol), HOAT (135 mg, 1 mmol), and DIPEA (350 μL, 2 mmol) in dry DMF (12.0 mL).
The mixture was shaken for 3 h at room temperature and then the solvents were filtered off.
The resin was washed with DMF (3 × 10 mL). The ester group of carboxyfluorescein was
deprotected with 20% piperidine (20 mL) for 30 min. The N-terminal Dde protection was
deprotected by treating the resin-bound peptide with hydrazine hydrate in DMF (2% v/v, 20
mL, 2 × 5 min). Finally, the side chain protected peptide was cleaved from the resin by
shaking the resins with a mixture of TFE/acetic acid/DCM (15 mL, 1:2:7 v/v/v) for 1 h. The
resin was filtered off, and the solution was evaporated to dryness under reduced pressure to
yield side-chain protected linear peptide. The cyclization and purification was carried out
according the described general method above used for other cyclic peptides to yield
fluorescence-labeled cyclic [KW]5. MALDI-TOF (m/z) [C109H127N21O17]: calcd,
2001.9719; found, 2000.9316 [M]+, 2023.0032 [M + Na]+, 2038.9458[M + K]+.
Synthesis of Fluorescence Labeled-βA-Linear(KWKWKWKWKW) (F′-(KW)5)—
The labeled linear sequence was assembled on H-Trp(Boc)-2 chlorotrityl resin (513 mg,
0.40 mmol, 0.78 mmol/g). The synthesis of the fluorescence-labeled side chain-protected
linear peptide was carried out according to the similar procedure that described above. The
peptide was assembled on resin using Dde-Lys(Fmoc)-OH at N-terminal. The Fmoc was
removed in the presence of piperidine (20%, DMF). After the coupling of β-alanine and
carboxyfluorscein in the side chain, the Dde protection at the N-terminal was removed by
reacting with 2% hydrazine hydrate in DMF followed by washing with DMF. Then, the
linear peptide was removed from the resin by using TFA/thioanisole/anisole/EDT (15 mL,
90:5:2:3 v/v/v/v) for 2 h to obtain the crude product. The crude peptide was precipitated by
the addition of cold diethyl ether (75 mL, Et2O). Reversed-phase Hitachi HPLC (L-2455)
and the gradient system described above were used for the purification of the peptide.
MALDI-TOF (m/z) [C109H129N21O18]: calcd, 2019.9824; found, 2019.8717 [M]+,
2042.8717 [M + Na]+, 2058.8717 [M + K]+.
HAuCl4 Reduction By Peptides Dissolved In DMSO/Water Mixtures—The
peptides were dissolved in 1 mL of deionized water in order to prepare a stock solution of 1
mM. The stock solution (1 mL, 1 mM) was physically mixed with HAuCl4 solution (1 mL,
1 mM) in deionized water to obtain AuNPs. The final concentrations of gold and peptides
were 500 μM. The formation of purple AuNPs was observed by the apparent change in the
color of solution and confirmed by UV-Vis spectroscopy.
UV-Vis Spectroscopy Studies—The formation of P-AuNPs was studied in the presence
of different peptides. In general, a peptide stock solution (1 mM) was mixed with an
aqueous solution of HAuCl4 (1 mM) at room temperature. The color of solution turned red
after 1 h due to the formation of peptide capped-AuNPs. UV-Vis spectroscopy study was
carried out using HAuCl4 (1 mM) and different cyclic peptides (1 mM) using 96-well plate,
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and the absorbance was read using SpectraMax M2 spectrophotometer (Molecular Devices,
CA) (Figure S1). The visible range was chosen because of the characteristic maxima peak of
AuNPs appeared around 520-560 nm. All experiments were performed in triplicate.
Encapsulation of Camptothecin (CPT)—CPT was dissolved in DMSO, and 10 μL of
10-3 M camptothecin solution was mixed with 100 μL of 10-4 M aqueous peptide solution in
a 1:1 molar ratio. CPT in DMSO was mixed with water as a negative control. Mixed
solution was incubated in a 96 well plate at room temperature for 4 h. Fluorescence of the
solution was measured using SpectraMax M2 fluorescence spectrophotometer (Molecular
Devices, CA) with excitation at 290 nm and emission at 360 nm.
Drug Loading—Doxorubicin (Dox) aqueous solution (100 μL, 100 μM) was added into
[KW]5-AuNPs solution (900 μL, 500 μM) with the concentration ratio of 1:5 for Dox to
peptide-capped AuNPs. The mixture was transferred into a 1 mL dialysis membrane (with
the cutoff molecular weight 1000 D; Float-A-Lyzer G2, Spectrum Labs). The membrane
was sealed and submerged into water (500 mL) as a medium. After stirring in dark for 24 h,
unloaded Dox in the mixture was collected and evaporated to reduce the volume. The
concentration of Dox was measured using a reverse phase HPLC system installed with
Hitachi premier C18 column (3 μm, 4.6 × 150 mm) at UV/Vis 490 nm wavelength. Mobile
phases were water (0.1% trifluoroacetic acid) and acetronitrile (0.1% trifluoroacetic acid).
The gradient of 10% to 90% acetonitrile was applied to separate the Dox peak from other
impurities. The calibration standard solutions were injected to quantify Dox in the sample
solution.
The loading efficiency was calculated using the following equation:
To measure the loading capacity, the amount of the AuNPs in the dialysis membrane was
measured after 24 h by using ICP-MS. The ICP-MS results showed the amount of AuNPs
were responsible for the encapsulation of Dox. Thus, the loading capacity was calculated
based on the following equation.
Transmission Electron Microscopy (TEM)—TEM analyses were conducted in JEOL
Transmission Electron Microscope (Tokyo, Japan) at an accelerating voltage 80 keV. The
stock solution (1 mL, 1 mM) was physically mixed with HAuCl4 solution (1 mL, 1 mM) in
deionized water to obtain AuNPs. The final concentrations of gold and peptides were 500
μM. The mixture was incubated for 12 days. TEM samples of c[KW]5-AuNPs and l(KW)5-
AuNPs were prepared by depositing a droplet of 5 μL of 0.5 mM solution in H2O on a
carbon-coated Cu support grid of mesh size 300 that were dried in air overnight.
Cell Culture—Human leukemia cell line CCRF-CEM (ATCC no. CCL-119), ovarian
carcinoma SK-OV-3 (ATCC no HTB-77), and colon myofibroblasts CCD-18Co (ATCC no.
CRL-1459) were obtained from American Type Culture Collection. Cells were grown on 75
cm2 cell culture flasks with RPMI-16 medium (for leukemia cells) and EMEM medium (for
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SK-OV-3 and CCD-18Co cells), supplemented with 10% fetal bovine serum (FBS), and 1%
penicillin-streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin in 0.9
% NaCl) in a humidified atmosphere of 5% CO2, 95% air at 37 °C.
Cytotoxicity Assay—SK-OV-3, CCRF-CEM, and CCD-18Co cells were seeded at 5,000
cells, 30,000 cells, and 3,000 cells, respectively, in 0.1 ml per well in 96-well plates 24 h
prior to the experiment. The old medium (EMEM containing FBS (10%)) was replaced (not
in case of CCRFCEM) by different concentrations of c[KW]5, l(KW)5, c[KW]5-AuNPs or
l(KW)5-AuNPs in serum containing medium and incubated for 24 h (or 72 h) at 37 °C in a
humidified atmosphere of 5% CO2. Cell viability was then determined by measuring the
fluorescence intensity at 490 nm using a SpectraMax M2 microplate spectrophotometer. The
percentage of cell survival was calculated as [(OD value of cells treated with the test mixture
of compounds) – (OD value of culture medium)]/[(OD value of control cells) – (OD value of
culture medium)] × 100% (Figure S2).
Flow Cytometry Studies—Human leukemia and ovarian carcinoma cells (CCRF-CEM
and SK-OV-3) were taken in 6-well plates (1 × 107 cells/well (CCERF-CEM) and 3 × 105
cells/well (SK-OV-3)) in opti-MEM. Then the fluorescence-labeled compound (F′-3TC, F′-
FTC, or F′-GpYEEI) (5 μM) was added to the different wells containing c[KW]5-AuNPs (25
μM), l(KW)5-AuNPs (25 μM), l(KW)5 (25 μM), or c[KW]5 (25 μM) in serum-free media.
The plates were incubated for 1 h at 37 °C. Cells, P-AuNPs, and the fluorescence-labeled
compound alone were used as negative controls. After 1 h incubation, the media containing
the peptide was removed. The cells were digested with 0.25% trypsin/EDTA (0.53 mM) for
5 min to remove any artificial surface binding. Then the cells were washed twice with PBS.
Finally, the cells were resuspended in flow cytometry buffer and analyzed by flow
cytometry (FACSCalibur™:Becton Dickinson) using FITC channel and CellQuest software.
The data presented were based on the mean fluorescence signal for 10,000 cells collected.
All assays were performed in triplicate.
In the case of fluorescence-labeled peptide gold nanoparticles (F′-Peptide-AuNPs) and their
corresponding peptides (F′-Peptide), SK-OV-3 cells were seeded in 6-well plates (3 × 105
cells/well) in opti-MEM. The F′-labeled compound (F′-c[KW]5, F′-l(KW)5, F′-c[KW]5-
AuNPs, or F′-l(KW)5-AuNPs (5 μM) was added to the various wells. The plates were
incubated for 1 h at 37 °C. Wells containing no treatment and 5-(6) carboxyfluorescein
(FAM) were used as negative controls. After 1 h incubation, the medium was removed. The
cells were digested with 0.25% trypsin/EDTA (0.53 mM) for 5 min to remove any artificial
surface association and to detect only intracellular uptake. Then the cells were washed twice
with PBS. Finally, the cells were resuspended in flow cytometry buffer and analyzed by
flow cytometry (FACSCalibur: Becton Dickinson) using FL2 channel and CellQuest
software. The data presented are based on the mean fluorescence signal for 10,000 cells
collected. All assays were performed in triplicate.
Cellular Uptake Studies In The Presence of Inhibitors—Human ovarian
adenocarcinoma cells (SK-OV-3) were seeded in six well plates (3 × 105 cells/well) in opti-
MEM. The cells were pre-incubated by various inhibitors including, nystatin (50 μg/ml),
chloroquine (100 μM), chlorpromazine (30 μM), methyl-β-cyclodextrin (2.5 mM), and 5-(N-
ethyl-N-isopropyl)amiloride (EIA, 50 μM) for 30 min. The treatment was removed, and the
cells were incubated with F′-l(KW)5-AuNPs or F′-c[KW]5-AuNPs (5 μM) a similar
concentration of inhibitors for 1 h. Consequently, similar FACS protocol was performed as
described above.
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Membrane Integrity Test—Ovarian carcinoma cells SK-OV-3 were grown in six well
plates (1 × 105 cells/well). Cells were treated with [KW]5-AuNPs (50 μM) and (KW)5-
AuNPs (50 μM) in serum-free media for 1 h at 37 °C. After 1 h incubation, the cells were
detached with trypsinization for 5 min followed by washing twice with PBS. Then they were
resuspended in serum-free media. Trypan blue (2 μL) was added into the cell suspension (18
μL) and incubated for 5 min. Finally, trypan bluestained cells were counted using cellometer
vision (Nexcelom Bioscience, Lawrence, MA, USA) (Figure S3).
Confocal Microscopy on Live Cells—Adherent SK-OV-3 cells were seeded with
EMEM media overnight on coverslips in six well plates (1×105 cells per well). Then, the
media were removed and washed with opti-MEM. The cells were treated with the mixture of
F′-3TC (5 μM) and c[KW]5-AuNPs (25 μM), and the mixture of F′-3TC (5 μM) and
l(KW)5-AuNPs (25 μM) in opti-MEM for 1 h at 37 °C. After 1 h incubation, the media
containing the treatments were removed followed by washing with PBS three times. To stain
the nuclei, cells were incubated with 4,6-diamidino-2-phenylindole (DAPI, 0.5 mL) solution
in PBS for 5 min. After the incubation, the cells were softly washed twice with PBS to
remove the excessive DAPI. The coverslips were mounted on a microscope slide with
mounting media with cells-attached side facing down. Laser scanning confocal microscopy
was carried out using Carl Zeiss LSM 700 system. The cells were imaged using FITC and
phase contrast channels. The fluorescence images were taken under 20 × objective. Blue and
green luminescent emissions from DAPI and FITC were excited at the wavelength of 405
nm and 488 nm, respectively. The emission wavelengths were ranged from 425 nm to 475
nm for DAPI and 500 nm to 550 nm for FITC. There was no interference between these two
channels. The scanning mode was in sequential frame.
Time-Dependent Antiproliferative Assay—The antiproliferative activity of CPT alone
and in the presence of c[KW]5-AuNPs against SK-OV-3 cells was determined by MTS
assay. All cells were plated overnight in 96-well plates with a density of 5000 cells per well
in 0.1 mL of appropriate growth medium at 37 °C. CPT alone (5 μM) or a combination of
CPT (5 μM) and c[KW]5-AuNPs (25 μM) were incubated with the cells for 4 h. Excess of
compounds was removed and washed by fresh media. The cells were kept in an incubator
for 24–72 h. The cells without compounds were included in each experiment as controls.
After 24 h, 48 h, and 72 h incubation, 20 μL of MTS solution was added and incubated for 2
h. The absorbance of the formazan product was measured at 490 nm using microplate
reader. The percentage of cell viability was calculated as (OD value of untreated cells - OD
value of treated cells)/OD value of untreated cells × 100%.
Intracellular Release of Dox—Intracellular release and accumulation of Dox were
determined in CCRF-CEM cells by HPLC analysis. CCRF-CEM cells were grown in 75
cm2 culture flasks with RPMI medium (containing 10% FBS and 1% penicillin-
streptomycin) to achieve ～70–80% confluence (1.2 × 107 cells/mL). The cells were
partitioned/transferred to culture plates (six well) having 1.2 × 107 cells per well in 2 mL of
medium. The treatment in fresh RPMI medium containing Dox-loaded c[KW]5-AuNPs
(7.5/37.5 μM) was added to cells, and they were incubated at 37 °C for different incubation
times including 2, 12, 24, and 48 h. After the incubation time, the cells were collected by
centrifugation. The medium was removed and cell pellets were washed with ice-cold PBS (5
mL) twice to remove any medium. The cell pellets were thoroughly extracted with an equal
volume of methanol, chloroform, and isopropanol mixture (4:3:1 v/v/v) and filtered through
0.2 μm filters. The solvents were evaporated under N2 gas. The released Dox was quantified
by reverse phase HPLC system with UV/Vis detector (490 nm) (Figures S4-S9, Supporting
Information). The HPLC condition was using mobile phase water (0.1% trifluoroacetic acid)
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and acetronitrile (0.1% trifluoroacetic acid) and the gradient of 10% to 90% acetonitrile as
described above in drug loading section.
Results and Discussion
Chemistry
A number of cyclic octapeptides containing diverse combination of amino acids including
c[KW]4, c[KF]4, c[KA]4, c[EL]4, c[RFEF]2, c[EK]4, c[RF]4, and c[RC]4 (Figure S1) were
synthesized by employing 9-fluorenylmethyoxycarbonyl (Fmoc)-based chemistry according
to the previously reported procedure.14,16 Synthesis of c[KW]4 and l[KW]4 is described in
Supporting Information (Schemes S1 and S2).
Fluorescently-labeled conjugates of linear (KW)5 and cyclic [KW]5 were synthesized as
described previously.14 For example, F′-l(KW)5 was synthesized by the Fmoc protection
group at the N-terminal was removed. Subsequent conjugation reaction with 5(6)-
carboxyfluorescein isobutyrate was performed in the presence of HOAt, PyAOP, and N,N-
diisopropylethylamine (DIPEA) in DMF:DCM followed by deprotection and cleavage from
the resin in the presence of reagent R afforded the crude product that was purified by
preparative reversed-phase HPLC (Scheme S1). The structures of all the final compounds
were confirmed by high-resolution MALDI TOF/TOF and/or high-resolution electrospray
mass spectrometry.
Evaluation of Cyclic and Linear Peptides for Generation of Peptide-AuNPs and
Characterization
All peptides were examined for their ability to generate AuNPs by direct addition of the
peptide solution (1 mM) into an aqueous solution of HAuCl4 (1 mM) at room temperature.
UV-Vis spectra and monitoring of surface plasmon resonance peak at ～550 nm showed that
among all peptides, c[KW]4 and the corresponding linear peptide l(KW)4 were able to
produce peptide capped AuNPs (P-AuNPs) (Figure S1).
Mechanistically, c[KW]4 acts as reducing and capping agent, making this method a one-step
(one-pot) reaction without any need for chemical modification on the surface of AuNPs.
Amino acids have been used as reducing agents. Among them, tryptophan (W) has been
shown to be the most efficient reducing agents among 20 amino acids.17 Addition of
positively charged residues, such as lysine (K) in the structure of the peptide enhances the
reduction through the favorable charge interactions with the chloroaurate anions.18
To optimize the yield of P-AuNPs by increasing the reducing and capping efficiency of the
peptide, cyclic c[KW]5 containing ten alternative tryptophan and lysine (Figure 1) was
synthesized. The corresponding linear peptide l(KW)5 (Figure 1) was also designed and
synthesized to determine the effect of the peptide cyclic nature of the peptide on the shape
and size of P-AuNPs. UV-Vis spectra of both c[KW]5-AuNPs and l(KW)5-AuNPs showed
also a SPR peak at approximately 550 nm.
Further studies were conducted by Transmission electron microscopy (TEM) to characterize
the size and shape of P-AuNPs. TEM images of c[KW]5-AuNPs and l(KW)5-AuNPs
showed that these two systems formed entirely different nanosized structures. c[KW]5-
AuNPs formed sponge-like agglomerates containing peptide and AuNPs containing peptide
and AuNPs with an approximate diameter size of 250-450 nm (Figure 2) along with some
isolated AuNPs in mostly spherical and triangular shapes (6-60 nm). Compared to cyclic
peptide-capped AuNPs, TEM images of 1(KW)5-AuNPs demonstrated ball-shaped
structures with the approximate diameter size of 900-1000 nm composed of a large number
of AuNPs (Figure 3). The majority of individual l(KW)5-AuNPs were found to be spherical
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and approximately in the size range of 4-35 nm. The distribution pattern of AuNPs in the
ball-shape structure of l(KW)5-AuNPs showed an organized arrangement (Figure 3). No
visible peptide agglomerates were observed. Cavities between AuNPs were found to be
tailored in a similar range size (approximately 45 ± 2 nm). The presence of the tryptophan in
the structure of the linear peptide induces presumably hydrophobic interactions that could be
an efficient driving force for the formation of this specific structure. c[KW]5 and l(KW)5
alone did not form any specific nanostructures under similar conditions, suggesting that the
binding between AuNPs and peptides contributes to different morphology in P-AuNPs.
These data showed that the cyclic nature and rigidity of the peptide in c[KW]5-AuNPs and
different orientation of amino acids in the skeleton of peptide generated a different
environment surrounding the complex that led to aggregation or agglomeration of the
peptides. This orientation altered the number of available tryptophan and/or lysine residues
in reduction of Au3+ reaction.18 However, l(KW)5 has more flexible conformation compared
to the corresponding conformationally constrained cyclic counterpart c[KW]5 during the
AuNPs formation. The presence of additional positively charge amino group and negatively
charge carboxylate at N-terminal lysine and C-terminal tryptophan, respectively, could also
contribute in intermolecular interactions of the peptide. Thus, the cyclic and linear nature of
the peptide and the orientation of amino acids were found to be responsible for the different
morphology and size of formed P-AuNPs.
Circular dichroism (CD) was used to obtain a better understanding about the effect of
AuNPs formation on the secondary structure of these peptides. CD experiment of aqueous
solution of peptides and their corresponding P-AuNPs (100 μM) was performed at room
temperature. CD spectra of c[KW]5 (Figure 4) revealed a negative band at approximately
216 nm and a positive band around 230 nm. Compared to c[KW]5, the linear counterpart
l(KW)5 showed a different CD spectra pattern with a negative band at 201 nm and a positive
band at 227 nm. However, the CD spectra of both c[KW]5-AuNPs and l(KW)5-AuNPs
exhibited relatively similar pattern with a minima at 204 ± 2 nm and a maxima at maxima at
229 ± 1 nm. Although two P-AuNPs showed approximately similar pattern and intensity,
l(KW)5-AuNPs (206 nm) minima was shifted compared to that of c[KW]5-AuNPs (203 nm).
The CD spectra demonstrated a significant decrease in spectral elipticity of both P-AuNPs
compared to their corresponding parent peptides, suggesting significant modification of
secondary structures upon reducing Au3+ and/or binding to AuNPs. These data show the
binding between peptides and AuNPs leads to the formation of c[KW]5-AuNPs and l(KW)5-
AuNPs with differential CD spectra pattern compared to the parent peptides.
Encapsulation of Camptothecin By Peptide-AuNPs
To evaluate the potential of c[KW]5-AuNPs and l(KW)5-AuNPs to encapsulate drugs,
camptothecin (CPT), a hydrophobic potent anticancer drug targeting topoisomerase I19 was
selected as a model drug for evaluation of loading using fluorescence spectroscopy.
Incubation of CPT with c[KW]5-AuNPs and l(KW)5-AuNPs demonstrated significant shift
in emission maxima of CPT. A characteristic maxima band of CPT alone at 458 nm was
shifted to 433 nm and 430 nm in the presence of c[KW]5-AuNPs and l(KW)5-AuNPs,
respectively (Figure S10). The spectral blue shift in the presence of c[KW]5-AuNPs and
l(KW)5-AuNPs was possibly due to partitioning of CPT into a hydrophobic core and
hydrophobic interactions. Moreover, the intensity of the maxima band was decreased that
could be due to the selfquenching of bound-drug and/or the result of the partitioning and
entrapment in the hydrophobic pocket generated by the P-AuNPs.20 These data exhibited
that the P-AuNPs were able to encapsulate CPT due to the generated hydrophobic pocket
possibly by tryptophan in the structure of the peptide.
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Drug Loading—To get a better understanding of the quantitative drug loading efficiency
of the system, Dox was selected as a model drug because of its stability and fluorescence
property. The loading measurement was performed based on the previously reported
method.27 Aqueous Dox solution (100 μL, 100 μM) was mixed with aqueous c[KW]5-
AuNPs solution (900 μL, 500 μM) to obtain 1:5 molar ratio. The unloaded Dox was
separated by using dialysis to analyze the Dox loading efficiency and loading capacity in the
c[KW]5-AuNPs. After 24 h stirring, the loading efficiency was found to be 72 ± 1% when
the weight ratio of Dox to c[KW]5-AuNPs in feed is 1:5. The loading capacity was
calculated to be 16 ± 1 % based on the weight ratio of Dox to c[WK]5-AuNPs (1:5) when
the amount of AuNPs was determined using inductively coupled plasma mass spectrometry
(ICP-MS).
Cytotoxicity of Peptide-AuNPs
Generated c[KW]5-AuNPs and l(KW)5-AuNPs did not show any significant toxicity in
human ovarian adecarcinoma (SK-OV-3), human leukemia (CCRF-CEM) cancer cells, and
normal human colon myofibroblast (CCD-18Co) cells at a concentration of 100 μM after 24
and 72 h incubation times (Figure S2). Thus, concentration of □100 μM was selected for
further cell-based studies. It is important to emphasize that the cytotoxicity of c[KW]5 and
l(KW)5 (100 μM) was decreased through P-AuNPs formation dramatically. For example,
c[KW]5 was found to be toxic in normal colon CCD-18Co cells (61.3% cell viability)
compared to c[KW]5-AuNPs (99.3% cell viability) after 24 h at a concentration of 100 μM.
These data indicate that the cytotoxicity of the parent peptide significantly reduces upon
generation of P-AuNPs.
Cellular Uptake of Peptide-AuNPs
To confirm the internalization of P-AuNPs alone, F′-l(KW)5-AuNPs and F′-c[KW]5-AuNPs
were prepared as described above by incubating of fluorescently-labeled conjugates of linear
(KW)5 and cyclic [KW]5, F′-l(KW)5 and F′-c[KW]5, with HAuCl4 solution according to the
previously reported procedure.15 Incubation of F′-l(KW)5-AuNPs and F′-c[KW]5-AuNPs
with SK-OV-3 cells showed 3.3- and 4.3-fold higher cellular uptake compared to the
corresponding fluorescently-labeled peptides F′-l(KW)5 and F′-c[KW]5, respectively, thus
suggesting the formation of P-AuNPs is crucial for the enhanced cellular permeability
(Figure 5). FACS results confirmed that F′-c[KW]5-AuNPs showed approximately 1.6-fold
higher cellular uptake than F′-l(KW)5-AuNPs, suggesting that the cyclic nature of the
peptide in P-AuNPs contributes to improving the cellular uptake.
To investigate whether c[KW]5-AuNPs and l(KW)5-AuNPs localize in different locations in
the cell, F′-l(KW)5-AuNPs (5 μM) and F′-c[KW]5-AuNPs (5 μM) were incubated with SK-
OV-3 for 1 h. 4′,6-Diamidino-2-phenylindole (DAPI) was employed as a marker of nucleus.
Confocal microscopy showed significantly higher nuclear localization of the cyclic peptide-
capped AuNPs (F′-c[KW]5-AuNPs) versus the corresponding linear system (F′-l(KW)5-
AuNPs) as shown by overlayed picture with DAPI (Figure 6).
Cells use different mechanisms to internalize macromolecules and particles, such as
phagocytosis, micropinocytosis, and receptor-mediated endocytosis (RME) pathways
including clathrin-mediated, caveolae-mediated, and caveolae/clathrin independent
endocytosis.21 To get a better understanding of the mechanism of peptide-capped gold
nanoparticles uptake by cells, the cellular uptake of fluorescein-labeled peptide capped gold
nanoparticles, F′-l(KW)5-AuNPs and F′-c[KW]5-AuNPs (5 μM), were tested quantitatively
in the presence of several inhibitors by using FACS including, nystatin, chloroquine,
chlorpromazine, methyl-β-cyclodextrin, and 5-(N-ethyl-N-isopropyl)- amiloride (EIA).
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As it is shown in Figure 7, the intracellular uptake of F′-l(KW)5-AuNPs and F′-c[KW]5-
AuNPs did not significantly change in SK-OV-3 cells in the presence of different endocytic
inhibitors after 1 h incubation, suggesting that the mechanism of cellular uptake is not
exclusively clathrin-mediated or caveolae-mediated endocytosis, and macropinocytosis.
These peptide-AuNPs provide an advantage to known gold nanoparticles and cell-
penetrating peptides that their uptake is dependent mainly on endocytotic entry.22
The surface decoration of AuNPs by amphipathic c[KW]5 and l(KW)5 peptides could
improve the interactions of lysine and tryptophan residues with the corresponding negatively
charged phospholipids and hydrophobic residues in lipid bilayer. This interaction could be a
strong driving force for the initial entry into the cell membrane. Hydrophobic interactions
generated by tryptophan residues and the lipids can potentially distort the outer phospholipid
monolayer. This process will be followed by peptide internalization and enhanced cellular
uptake of the cargo. The nature of the peptide in surface of AuNPs is an important parameter
that can alter the mechanism of nanoparticle uptake by cells. Further investigation is
required to pinpoint the detailed mechanism of cell entry by these P-AuNPs.
The cellular membrane integrity in SK-OV-3 cells was examined in the presence of c[KW]5-
AuNPs and l(KW)5-AuNPs and using trypan blue and showed no significant difference to
the control cells (Figure S3), ruling out the damage of the plasma membrane by P-AuNPs at
50 μM and confirming that the highly efficient transport of the complex was not a result of
decreased cellular membrane integrity.
Evaluation of Peptide-AuNPs As Molecular Transporters
To evaluate P-AuNPs as molecular transporters, model experiments with anti-HIV drugs 2′,
3′-dideoxy-5-fluoro-3′-thiacytidine (emtricitabine, FTC) and 2′,3′-didehydro-2′,3′-
dideoxythymidine (lamivudine, 3TC) as cargo drugs were performed. FTC and 3TC are
nucleoside reverse transcriptase inhibitors those blocks HIV-1 and hepatitis B virus
replication.22 The efficient cellular uptake of FTC and 3TC are critical for anti-HIV activity.
To monitor the molecular transporter ability of P-AuNPs, carboxyfluorescein derivatives of
FTC (F′-FTC) and 3TC (F′-3TC) were synthesized as described previously, where F′=
fluorescein.24,25
CCRF-CEM cells were incubated with F′-FTC and F′-3TC (5 μM) in the presence or
absence of diluted carriers c[KW]5-AuNPs and l(KW)5-AuNPs (25 μM) and their parent
peptides for 1 h at 37 °C and then treated with trypsin to remove cell surface-bound drugs.
Intracellular uptake of F′-FTC and F′-3TC (5 μM) was measured in cells using fluorescence
activated cell sorter (FACS). FACS showed significantly higher fluorescence signals in cells
treated with F′-Drug-loaded P-AuNPs compared to those with drug alone. The cellular
uptake of F′-drug-loaded c[KW]5-AuNPs and F′-drug–loaded l(KW)5-AuNPs were found to
be 5.2–5.3- and 2.5–2.9-fold higher for F′-FTC and F′-3TC, respectively, than those of drug
alone respectively (Figure 8), suggesting that the uptake of drugs is facilitated by P-AuNPs.
The results showed that parent cyclic or linear parent peptides did not improve the cellular
uptake of drugs. However, after the formation of P-AuNPs, the cellular uptake of drugs was
increased significantly. c[KW]5-AuNPs were found to be more efficient transporter than
l(KW)5-AuNPs, while c[KW]5 and l(KW)5 exhibited similar results. These data suggest that
a non-cell penetrating cyclic peptide can be converted to cell-penetrating P-AuNPs,
presumably due to the new orientation of amino acids and the secondary structure in
peptides as shown with CD in the presence of generated AuNPs for drug entrapment.
To visualize the enhancement of the cellular uptake of drugs, F′-3TC was used as a model
for confocal microscopy in SK-OV-3 cells. Confocal microscopy showed nuclear
localization of F′-3TC–loaded c[KW]5-AuNPs compared to the corresponding linear system
Shirazi et al. Page 12
Mol Pharm. Author manuscript; available in PMC 2014 August 05.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
and drug alone. F′-3TC-loaded l(KW)5-AuNPs exhibited a modest fluorescence mostly in
the cytoplasm of the cells. However, incubation of cells with F′-3TC alone did not show any
fluorescence intensity in cells. These data confirm that the cyclic nature of the peptide is
critical for the enhanced cellular permeability (Figure 9) and the nuclear targeting delivery
of cargos.
Thus, differential application of linear and cyclic [KW]5-AuNPs was discovered for
localization of fluorescence-labeled-3TC. Confocal microscopy revealed the localization of
fluorescence-labeled-3TC in the presence of c[KW]5-AuNPs mostly in nucleus in SK-OV-3
cells after 1 h. On the other hand, l(KW)5-AuNPs delivered fluorescence-labeled-3TC in
cytoplasm. Furthermore, c[KW]4-AuNPs offered two major advantages over c[RW]4-
AuNPs that we previously reported15. First, the reaction time for the formation of c[KW]4-
AuNPs (1 h) was significantly shorter compared to that of c[RW]4-AuNPs (4-8 h). The
Surface Plasmon Resonance peak for both c[KW]4-AuNPs and c[RW]4-AuNPs15 was
compared by using UV-Vis spectroscopy (Figure S11) after 1 h. The results showed that
c[KW]4-AuNPs formed faster than c[RW]4-AuNPs. Second, the size and morphology of
nanoparticles can be used to control the amount of intracellular uptake of AuNPs by cells.
Intracellular accumulation of 233 ng and 288 ng of c[RW]4-AuNPs and c[KW]4-AuNPs was
detected, respectively, in SK-OV-3 cells after 24 h incubation15 as measured by ICP-MS.
The molecular transporting efficiency of P-AuNPs for cell-impermeable negatively charges
phosphopeptides was also evaluated using flow cytometry. The phosphopeptide do not cross
the cell-membrane readily because of the presence of the negatively charged phosphate
group. The pTyr-Glu-Glu-Ile (GpYEEI) peptide template has been reported to be an optimal
binding sequence for the Src SH2 domain of Src kinase.25 The cellular uptake of F′-GpYEEI
was monitored in the presence of P-AuNPs in SK-OV-3 cells. FACS analysis showed that
the cellular uptake of F′-GpYEEI was enhanced 3.5- and 12.8-fold by l(KW)5-AuNPs and
c[KW]5-AuNPs, respectively (Figure 10), suggesting that these systems may function as a
delivery tools for F′-GpYEEI. c[KW]5-AuNPs improved the cellular uptake of F′-GpYEEI
4.2-fold higher when compared to l(KW)5-AuNPs, suggesting the critical role of the cyclic
peptide in improving the cellular uptake. These results are consistent with cellular uptake
studies of lamivudine and emtricitabine.
Considering the significant enhancement of F′-GpYEEI in the presence of P-AuNPs (Figure
10), confocal microscopy was used to confirm the cellular uptake of this negatively charged
phosphopeptide in the presence and absence of P-AuNPs. Thus, confocal microscopy was
conducted by measuring the fluorescence intensity of F′-GpYEEI-loaded P-AuNPs
compared to F′-GpYEEI alone in SK-OV-3 cells. 4′,6-Diamidino-2-phenylindole (DAPI)
was employed as a marker of nucleus. The cells were incubated with F′-GpYEEI-loaded
c[KW]5-AuNPs, F′-GpYEEI-loaded L[KW]5-AuNPs, and F′-GpYEEI alone. No green
fluorescence was observed for the parent fluorescence-labeled phosphopeptide, suggesting
that F′-GpYEEI alone did not cross the membrane because of the presence of negative
charge phosphate. As shown in Figure 11, the cell nuclei stained by DAPI (blue) were
circumvented by the green fluorescence showing the fluorescent-labeled phosphopeptide
localized in the cytoplasm in the presence of L[KW]5-AuNPs (Figure 11b). However, the
presence of c[KW]5-AuNPs led an overlay of green and blue fluorescence signals revealing
the localization of the phosphopeptide mostly in the nuclei of SK-OV-3 cells (Figure 11c).
These results indicated that the presence of P-AuNPs is critical to improve the cellular
uptake of cell-impermeable phosphopeptide. Furthermore, the linear or cyclic nature of the
peptide determines the final destination of the cargo.
Time-Dependent Antiproliferative Assay—To determine whether c[KW]5-AuNPs can
be exploited for the delivery of biologically relevant doses of CPT to cells, the
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antiproliferative activity of CPT was evaluated in SK-OV-3 cells in the presence and
absence of peptide-capped AuNPs in a time-dependent manner. The antiproliferative activity
of CPT (5 μM) in the presence of the c[KW]5-AuNPs was improved by approximately 9%,
32%, and 33% compared to that of CPT alone after 24, 48, and 72 h incubation, respectively
(Figure 12). Time-dependent inhibitory effect on the cell proliferation of SK-OV-3 cells
suggests that the sustained intracellular release of CPT and improved efficacy of the
compound. c[KW]5-AuNPs alone did not show any toxicity in SK-OV-3 cells under similar
condition, suggesting that the higher antiproliferative is possibly related to the enhanced
uptake of the drug in the presence of the peptide-capped AuNPs and intracellular release of
CPT.
Intracellular Release of Dox—To investigate the kinetics of drug release in cells, Dox
was selected as a model drug. The intracellular release of Dox in the presence of the
c[KW]5-AuNPs in CCRF-CEM cells was monitored by HPLC. The CCRF-CEM cells (1.2 ×
107) were incubated with Dox (7.5 μM)-loaded c[KW]5-AuNPs (37.5 μM) for different
times including 2, 12, 24, and 48 h. HPLC analysis at 490 nm and a specific time intervals
after cellular lysis was used to measure the quantity of the released Dox. The data exhibited
that the intracellular release of Dox occurred in a time-dependent manner. Dox was
observed at 15.8-15.9 min in the HPLC profile (Figures S4-S9, Supporting Information).
HPLC data showed that approximately 30, 35, 55, and 88% of Dox was released
intracellularly within 2, 12, 24, and 48 h, respectively. These data suggest the sustained
release of Dox contributes to overall activity of the Dox–loaded c[KW]5-AuNPs as a
potential prodrug.
Conclusions
In conclusion, a new class of DDS containing AuNPs and peptides with tryptophan and
lysine residues were generated under a mild reaction condition. Cyclic and linear peptide
capped-AuNPs (l(KW)5-AuNPs and c[KW]5-AuNPs) exhibited entirely different
morphology and sizes. Both l(KW)5-AuNPs and c[KW]5-AuNPs showed minimal
cytotoxicity at 100 μM. P-AuNPs were able to entrap hydrophobic CPT through non-
covalent interactions, and act as molecular transporters of fluorescence-labeled lamivudine,
emtricitabine, and a phosphopeptide (GpYEEI) intracellularly. High cellular internalization
of the labeled drugs by P-AuNPs suggests the potential application of P-AuNPs as molecular
transporters. Confocal microscopy showed that l(KW)5-AuNPs and c[KW]5-AuNPs
delivered cargos to different destinations in cells e.g. cytoplasm and nucleus, respectively.
The present results provide insights for generation of a new class of peptide-capped metal
nanoparticles as cellular delivery transporters.
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Figure 1.
Chemical structures of synthesized peptides.
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Figure 2.
TEM images of c[KW]5-AuNPs.
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Figure 3.
TEM images of l(KW)5-AuNPs.
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Figure 4.
Comparative CD of cyclic c[KW]5, linear l(KW)5, and compared to c[KW]5-AuNPs and
l(KW)5-AuNPs.
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Figure 5.
Cellular uptake of F′-l(KW)5-AuNPs and F′-c[KW]5-AuNPs (5 μM) versus the
corresponding fluorescently-labeled peptides F′-l(KW)5 and F′-c[KW]5 (5 μM) after 1 h
incubation.
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Figure 6.
Confocal microscope images of F′-l(KW)5-AuNPs (5 μM) and F′-c[KW]5-AuNPs (5 μM)
uptake by SK-OV-3 cells after 1 h incubation.
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Figure 7.
Cellular uptake of (a) F′-l(KW)5-AuNPs (5 μM) and (b) F′-c[KW]5-AuNPs (5 μM) in the
absence or presence of different endocytic inhibitors in SK-OV-3 cells after 1 h.
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Figure 8.
Cellular uptake studies for F′-FTC and F′-3TC alone (5 μM) in the presence of cyclic and
linear peptides and their corresponding P-AuNPs (25 μM) after 1 h incubation.
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Figure 9.
Confocal microscope images of F′-3TC (5 μM) uptake by SK-OV-3 cells in the presence of
l(KW)5-AuNPs and c[KW]5-AuNPs (25 μM) after 1 h incubation.
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Figure 10.
Cellular uptake of F′-GpYEEI (5 μM) in the presence of l(KW)5-AuNPs, c[KW]5-AuNPs,
l(KW)5, and c[KW]5 (25 μM) after 1 h incubation.
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Figure 11.
Confocal microscope images of F′-GpYEEI (5 μM) uptake by SK-OV-3 cells in the
presence of l(KW)5-AuNPs and c[KW]5-AuNPs (25 μM) after 1 h incubation.
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Figure 12.
Time-dependent antiproliferative assay of CPT in the absence and presence of c[KW]5-
AuNPs.
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